EP2797640B1 - Fibrous structure - Google Patents

Fibrous structure Download PDF

Info

Publication number
EP2797640B1
EP2797640B1 EP12823134.7A EP12823134A EP2797640B1 EP 2797640 B1 EP2797640 B1 EP 2797640B1 EP 12823134 A EP12823134 A EP 12823134A EP 2797640 B1 EP2797640 B1 EP 2797640B1
Authority
EP
European Patent Office
Prior art keywords
coating
structure according
blood
fibers
permeability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12823134.7A
Other languages
German (de)
French (fr)
Other versions
EP2797640A1 (en
EP2797640B8 (en
Inventor
Christoph Classen
Swen FRANZEN
Harrie VAN BAARS
Wolfgang Witt
Andreas Henseler
Frank Willems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Occlutech Holding AG
Original Assignee
NonWoTecc Medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NonWoTecc Medical GmbH filed Critical NonWoTecc Medical GmbH
Publication of EP2797640A1 publication Critical patent/EP2797640A1/en
Publication of EP2797640B1 publication Critical patent/EP2797640B1/en
Application granted granted Critical
Publication of EP2797640B8 publication Critical patent/EP2797640B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
    • D04H1/4326—Condensation or reaction polymers
    • D04H1/4358—Polyurethanes
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/58—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/58—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives
    • D04H1/64—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives the bonding agent being applied in wet state, e.g. chemical agents in dispersions or solutions
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
    • D04H3/005—Synthetic yarns or filaments
    • D04H3/009—Condensation or reaction polymers
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
    • D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
    • D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
    • D04H3/07—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments otherwise than in a plane, e.g. in a tubular way

Definitions

  • the invention relates to a structure with locally bonded fibers having a permeability to air between 0.5 ml / min * cm 2 and 1.5 ml / min * cm 2 .
  • nonwovens are used as medical nonwovens and can be flat, curved, flexible or in particular also cylindrical. Depending on the embodiment, they are suitable for permanent use in the human body as an implant. This applies in particular to nonwovens made of biocompatible polyurethane, which can be used, for example, in a tubular shape as a vascular prosthesis. In this case, the nonwoven material can be used to form a tube wall, by which a channeling of blood for the reconstruction of degenerated blood vessels is possible.
  • EP 2 083 750 A1 and the WO 2011 054 932 A1 which describe such nonwovens, is incorporated by reference.
  • the material for the production of vascular prostheses must meet many requirements due to its properties, in order to be able to be used permanently for the formation of an artificial blood vessel. In addition to the sufficient mechanical and biological stability, this is above all the biological compatibility of the material, which is a basic prerequisite for the suitability for the production of an implantable medical device.
  • a vascular prosthesis should provide reliable and permanent delivery of blood flow without leakage or occlusion of the prosthetic lumen during use.
  • vascular prosthesis Apart from ruptures as the cause of leaks, it is essentially the material of the vascular prosthesis itself that can produce a leakage of blood.
  • a woven textile as a prosthesis wall material is mentioned, which due to its porous structure does not have a reliable seal against blood loss.
  • bleeding complications occur regularly, which is reduced after a long time by the onset of blood clotting and the resulting sealing of the pores.
  • auxiliaries in the form of a sealing material are used for such materials in order to reduce the severe bleeding complications.
  • Such material is used in the DE 600 03 046 T2 described.
  • the structure used in the present invention has such a low porosity that bleeding through the prosthesis does not occur after the bloodstream has been opened.
  • the permeability is chosen so that the blood cells entering the structure, and in particular a nonwoven, immediately clog the pores of the material.
  • Closures of the prosthetic lumen are generally biological reactions to the foreign material. These occlusions are mainly caused by hyperplasia (excessive cell growth) on the anastomoses or thrombosis in the bloodstream.
  • the structure used in this invention has, in particular as a nonwoven material, a similar compliance as a human artery.
  • Thrombosis in the lumen of a vascular prosthesis is predominantly due to activation of the platelets on the foreign material.
  • the material itself or its surface structure with the associated flow phenomena on the surface of the trigger of such activation is predominantly due to activation of the platelets on the foreign material.
  • the medical fleece of the company Nonwotecc which is in the EP 2 083 750 A1 and the WO 2011 054 932 A1 described has structural Features of an extracellular matrix, so that can settle on the inner surface of a prosthesis made of this material endothelial cells and spread.
  • the consequence of this cell growth is the formation of a luminal endothelial cell layer which completely obscures the underlying prosthetic material and thus significantly reduces coagulation activation in the blood.
  • the base material used to make the web has very good biocompatible properties, which causes only minimal irritation of the platelets.
  • the elastic properties of the structure and in particular of the nonwoven material are dimensioned such that the vascular prosthesis produced therefrom has a similar compliance to the natural arterial vessel.
  • the object of the invention is to avoid undesired cell attachment to the structure and, when used as a vascular prosthesis, to increase the patency rate of the artificial vessel.
  • a defined area of the material is subjected to a defined air pressure and then the air volume flow passing through the material is measured. This results in a special porosity, which can also be specified independently of the measurement method, for example, as an air resistance value.
  • the fibers are made of polyurethane.
  • the structure may comprise a nonwoven as it is for example in the WO 2008/049386 A1 is described.
  • An advantageous embodiment provides that the fibers are glued to a cylinder and the coating is arranged on the cylinder inside. This coating smoothes protruding, possibly broken fibers, which can lead to an activation of the platelets in the passing blood (thrombus formation.) In addition, the penetration of growth factors from the surrounding wound area is reduced, thereby reducing the risk of hyperplasia in the anastomotic area.
  • the coating of the inner surface of a vascular prosthesis made of a medical nonwoven surprisingly allows a further increase in the patency rate.
  • the coating has gelatin, collagens and / or fibrin.
  • gelatin can be absorbed after specific periods to be set in order to enable deposition of endothelial cells on the underlying fiber structure.
  • a coating of gelatin, fibrin and / or collagen levels the microscopically rough surface of the nonwoven material, thereby reducing the flow-induced activation of the platelets. After a defined time, which can be set by the production of this coating, the coating is absorbed in the blood stream and gradually exposes the underlying nonwoven structure, on which now the endothelial cells can settle.
  • the coating described here also reduces the risk of hyperplasia, since it leads to increased sealing the inside of the vessel comes to the outside, which prevents the influx of growth factors from the wound area surrounding the vessel. These growth factors obviously have a promoting effect on the development of hyperplasia in the lumen of the prosthesis.
  • the suppression of hyperplasia can additionally be achieved by the incorporation of medicinal active substances into the coating, which are released in a time-controlled manner by the absorption of the coating. It is therefore proposed that the coating comprises a drug. To prevent inflammation, silver ions can be incorporated into the coating.
  • the coating can be slowly absorbed in an implant, in particular an implanted artificial vessel. It is advantageous if it is absorbed after one to 30 days and preferably after 2 to 14 days to a maximum of 10% of the original amount.
  • the measuring method is an in vivo model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)

Description

Die Erfindung betrifft eine Struktur mit stellenweise miteinander verklebten Fasern, die eine Durchlässigkeit für Luft zwischen 0,5 ml/min*cm2 und 1,5 ml/min*cm2 aufweisen.The invention relates to a structure with locally bonded fibers having a permeability to air between 0.5 ml / min * cm 2 and 1.5 ml / min * cm 2 .

Derartige Vliese werden als medizinische Vliese eingesetzt und können plan, gebogen, flexibel oder insbesondere auch zylinderförmig sein. Je nach Ausführungsform sind sie dazu geeignet, als Implantat dauerhaft im menschlichen Körper eingesetzt zu werden. Dies trifft insbesondere auf Vliese aus biokompatiblem Polyurethan zu, die z.B. in röhrenförmiger Gestalt als Gefäßprothese eingesetzt werden können. In diesem Fall kann das Vliesmaterial dazu verwendet werden, eine Rohrwandung zu bilden, durch die eine Kanalisierung von Blut zur Rekonstruktion von degenerierten Blutgefäßen möglich wird. Auf die EP 2 083 750 A1 und die WO 2011 054 932 A1 , die derartige Vliese beschreiben, wird vollinhaltlich Bezug genommen.Such nonwovens are used as medical nonwovens and can be flat, curved, flexible or in particular also cylindrical. Depending on the embodiment, they are suitable for permanent use in the human body as an implant. This applies in particular to nonwovens made of biocompatible polyurethane, which can be used, for example, in a tubular shape as a vascular prosthesis. In this case, the nonwoven material can be used to form a tube wall, by which a channeling of blood for the reconstruction of degenerated blood vessels is possible. On the EP 2 083 750 A1 and the WO 2011 054 932 A1 , which describe such nonwovens, is incorporated by reference.

Das Material zur Herstellung von Gefäßprothesen muss durch seine Eigenschaften viele Anforderungen erfüllen, um dauerhaft zur Bildung eines künstlichen Blutgefäßes verwendet werden zu können. Neben der ausreichenden mechanischen und biologischen Stabilität ist dies vor allem auch die biologische Verträglichkeit des Materials, welche eine Grundvorrausetzung für die Eignung zur Herstellung eines implantierbaren Medizinproduktes ist.The material for the production of vascular prostheses must meet many requirements due to its properties, in order to be able to be used permanently for the formation of an artificial blood vessel. In addition to the sufficient mechanical and biological stability, this is above all the biological compatibility of the material, which is a basic prerequisite for the suitability for the production of an implantable medical device.

Eine Gefäßprothese sollte eine zuverlässige und dauerhafte Bahnung des Blutstroms gewährleisten, ohne dass es im Laufe der Anwendung zu Undichtigkeiten oder Verschlüssen des Prothesenlumens kommt.A vascular prosthesis should provide reliable and permanent delivery of blood flow without leakage or occlusion of the prosthetic lumen during use.

Sieht man von Rupturen als Ursache von Undichtigkeiten ab, ist es im Wesentlichen das Material der Gefäßprothese selber, welches eine Leckage von Blut erzeugen kann. Beispielhaft sei hier die Verwendung eines gewebten Textils als Prothesenwandmaterial erwähnt, welches aufgrund seiner porösen Struktur keine zuverlässige Abdichtung gegen Blutverlust aufweist. Nach Implantation kommt es regelmäßig zu Blutungskomplikationen, die erst nach einer längeren Zeit durch Einsetzen der Blutgerinnung und der dadurch verursachten Abdichtung der Poren reduziert wird. Um diesen Prozess zu beschleunigen werden für solche Materialien Hilfsmittel in Form eines Dichtungsmaterials eingesetzt, um die starken Blutungskomplikationen zu reduzieren. Ein derartiges Material wird in der DE 600 03 046 T2 beschrieben.Apart from ruptures as the cause of leaks, it is essentially the material of the vascular prosthesis itself that can produce a leakage of blood. By way of example, the use of a woven textile as a prosthesis wall material is mentioned, which due to its porous structure does not have a reliable seal against blood loss. After implantation bleeding complications occur regularly, which is reduced after a long time by the onset of blood clotting and the resulting sealing of the pores. To speed up this process, auxiliaries in the form of a sealing material are used for such materials in order to reduce the severe bleeding complications. Such material is used in the DE 600 03 046 T2 described.

Die in der vorliegenden Erfindung verwendete Struktur besitzt konstruktionsbedingt eine derart geringe Porosität, dass es nach Eröffnung der Blutbahn nicht zu einer Blutung durch die Prothese kommt. Die Durchlässigkeit ist so gewählt, dass die in die Struktur und insbesondere in ein Vlies eindringenden Blutzellen sofort die Poren des Materials verstopfen. Zudem kommt es zu einer Gerinnungsreaktion in dem Material, welche zusätzlich die Gefäßwandung abdichtet.By design, the structure used in the present invention has such a low porosity that bleeding through the prosthesis does not occur after the bloodstream has been opened. The permeability is chosen so that the blood cells entering the structure, and in particular a nonwoven, immediately clog the pores of the material. In addition, there is a coagulation reaction in the material, which additionally seals the vessel wall.

Verschlüsse des Prothesenlumens sind im Allgemeinen biologische Reaktionen auf das Fremdmaterial. Diese Verschlüsse werden im Wesentlichen verursacht durch Hyperplasie (überschießendes Zellwachstum) an den Anastomosen oder einer Thrombose in der Blutbahn.Closures of the prosthetic lumen are generally biological reactions to the foreign material. These occlusions are mainly caused by hyperplasia (excessive cell growth) on the anastomoses or thrombosis in the bloodstream.

In der Wissenschaft wird als Hauptursache für das Auftreten einer Hyperplasie an den Anastomosen ein Compliance-Mismatch genannt. Dieses Merkmal tritt dann in Erscheinung, wenn sich die Dehneigenschaften des Prothesenmaterials signifikant von denen des nativen Gefäßes unterscheiden. Die bei dieser Erfindung verwendete Struktur besitzt insbesondere als Vliesmaterial eine ähnliche Compliance wie eine menschliche Arterie.In science, the main cause of the occurrence of hyperplasia in the anastomoses is called a compliance mismatch. This feature occurs when the stretch characteristics of the prosthetic material differ significantly from those of the native vessel. The structure used in this invention has, in particular as a nonwoven material, a similar compliance as a human artery.

Eine Thrombose im Lumen einer Gefäßprothese entsteht überwiegend aufgrund einer Aktivierung der Thrombozyten an dem Fremdmaterial. Dabei können das Material selber oder seine Oberflächenstruktur mit den damit verbundenen Strömungsphänomenen an der Oberfläche der Auslöser einer solchen Aktivierung sein.Thrombosis in the lumen of a vascular prosthesis is predominantly due to activation of the platelets on the foreign material. In this case, the material itself or its surface structure with the associated flow phenomena on the surface of the trigger of such activation.

Ziel der Bereitstellung eines optimalen Materials für eine Gefäßprothese oder eine flächige Abdichtung eines Blutraumes ist es also, dass das Material den Blutzellen gegenüber nicht als störendes Fremdmaterial erscheint. Dazu werden verschiedene technologische Ansätze verfolgt.The aim of providing an optimal material for a vascular prosthesis or a surface seal of a blood space, it is therefore that the material does not appear to the blood cells as a disturbing foreign material. For this purpose, various technological approaches are pursued.

Das medizinische Vlies der Firma Nonwotecc, das in der EP 2 083 750 A1 und der WO 2011 054 932 A1 beschrieben ist, besitzt strukturelle Merkmale einer extrazellulären Matrix, so dass sich auf der Innenoberfläche einer aus diesem Material hergestellten Prothese Endothelzellen ansiedeln und verbreiten können. Die Folge dieses Zellwachstums ist die Ausbildung einer luminalen Endothelzellschicht, die das darunterliegende Prothesenmaterial vollständig verdeckt, und somit die Gerinnungsaktivierung im Blut deutlich reduziert.The medical fleece of the company Nonwotecc, which is in the EP 2 083 750 A1 and the WO 2011 054 932 A1 described has structural Features of an extracellular matrix, so that can settle on the inner surface of a prosthesis made of this material endothelial cells and spread. The consequence of this cell growth is the formation of a luminal endothelial cell layer which completely obscures the underlying prosthetic material and thus significantly reduces coagulation activation in the blood.

Das zur Herstellung des Vlieses verwendete Grundmaterial besitzt sehr gute biokompatible Eigenschaften, welche nur eine minimale Reizung der Thrombozyten hervorruft.The base material used to make the web has very good biocompatible properties, which causes only minimal irritation of the platelets.

Letztlich sind die elastischen Eigenschaften der Struktur und insbesondere des Vliesmaterials derart dimensioniert, dass die daraus hergestellte Gefäßprothese eine dem natürlichen arteriellen Gefäß ähnliche Compliance aufweist.Ultimately, the elastic properties of the structure and in particular of the nonwoven material are dimensioned such that the vascular prosthesis produced therefrom has a similar compliance to the natural arterial vessel.

Ausgehend hiervon liegt der Erfindung die Aufgabe zu Grunde, eine unerwünschte Zellanlagerung an der Struktur zu vermeiden und bei der Verwendung als Gefäßprothese die Offenheitsrate des künstlichen Gefäßes zu erhöhen.Proceeding from this, the object of the invention is to avoid undesired cell attachment to the structure and, when used as a vascular prosthesis, to increase the patency rate of the artificial vessel.

Dies wird durch eine mindestens einseitige Beschichtung erzielt, die die Durchlässigkeit der Struktur auf unter 0,2 ml/min*cm2 reduziert.This is achieved by an at least one sided coating which reduces the permeability of the structure to less than 0.2 ml / min * cm 2 .

Somit wird eine relativ dichte Membran beschichtet, obwohl zur Erhöhung der Dichtheit eine Beschichtung nicht mehr notwendig wäre und eine poröse Oberfläche gut für das Zellwachstum wäre.Thus, a relatively dense membrane is coated, although to increase tightness, a coating would no longer be necessary and a porous surface would be good for cell growth.

Zur Bestimmung der Permeabilität/Porosität des Vlieses wird eine definierte Fläche des Materials mit einem definierten Luftdruck beaufschlagt und anschließend der durch das Material strömende Luftvolumenstrom gemessen. Dadurch ergibt sich eine spezielle Porosität, die auch unabhängig von der Meßmethode beispielsweise als Luftwiderstandswert angegeben werden kann.To determine the permeability / porosity of the nonwoven, a defined area of the material is subjected to a defined air pressure and then the air volume flow passing through the material is measured. This results in a special porosity, which can also be specified independently of the measurement method, for example, as an air resistance value.

Vorteilhaft ist es, wenn die Fasern aus Polyurethan bestehen.It is advantageous if the fibers are made of polyurethane.

Insbesondere zur Herstellung künstlicher Gefäße kann die Struktur ein Vlies aufweisen wie es beispielsweise in der WO 2008/049386 A1 beschrieben ist.In particular, for the production of artificial vessels, the structure may comprise a nonwoven as it is for example in the WO 2008/049386 A1 is described.

Eine vorteilhafte Ausführungsvariante sieht vor, dass die Fasern zu einem Zylinder verklebt sind und die Beschichtung an der Zylinderinnenseite angeordnet ist. Diese Beschichtung glättet abstehende, ggf. gebrochene Fasern, die zu einer Aktivierung der Thrombozyten im vorbeiströmenden Blut führen können (Thrombenbildung.) Außerdem wird das Eindringen von Wachstumsfaktoren aus dem umliegenden Wundbereich vermindert, um dadurch die Gefahr einer Hyperplasie im Anastomosenbereich zu reduzieren.An advantageous embodiment provides that the fibers are glued to a cylinder and the coating is arranged on the cylinder inside. This coating smoothes protruding, possibly broken fibers, which can lead to an activation of the platelets in the passing blood (thrombus formation.) In addition, the penetration of growth factors from the surrounding wound area is reduced, thereby reducing the risk of hyperplasia in the anastomotic area.

Die Beschichtung der Innenoberfläche einer Gefäßprothese aus einem medizinischen Vlies ermöglicht überaschenderweise eine weitere Erhöhung der Offenheitsrate.The coating of the inner surface of a vascular prosthesis made of a medical nonwoven surprisingly allows a further increase in the patency rate.

Erste Untersuchungen lassen vermuten, dass die Wahrscheinlichkeit einer dauerhaften Offenheit der Prothese dann am größten ist, wenn es zunächst nach dem initialen Blutkontakt mit der Protheseninnenoberfläche zu einer möglichst geringen Fremdkörperreaktion kommt. Nach dieser ersten Kontaktzeit sollte eine dauerhafte autologe Beschichtung der Materialoberfläche von statten gehen, die die Innenoberfläche der Prothese möglichst als körpereigenes Gewebe darstellen lässt. Eine solche autologe Beschichtung besteht im optimalen Fall aus einer geschlossenen Endothelzellschicht.Preliminary investigations suggest that the likelihood of a permanent openness of the prosthesis is greatest when it first comes to the least possible foreign body reaction after the initial blood contact with the prosthetic inner surface. After this first contact time, a permanent autologous coating of the material surface should be provided which, if possible, makes the inner surface of the prosthesis represent the body's own tissue. Such an autologous coating consists in the optimal case of a closed endothelial cell layer.

Vorteilhaft ist es, wenn die Beschichtung Gelatine, Kollagene und/oder Fibrin aufweist. Insbesondere Gelatine kann nach gezielt einzustellenden Zeiträumen resorbiert werden, um eine Anlagerung von Endothelzellen auf der darunterliegenden Faserstruktur ermöglichen zu können.It is advantageous if the coating has gelatin, collagens and / or fibrin. In particular, gelatin can be absorbed after specific periods to be set in order to enable deposition of endothelial cells on the underlying fiber structure.

Eine Beschichtung aus Gelatine, Fibrin und/oder Kollagen ebnet die mikroskopisch raue Oberfläche des Vliesmaterials und reduziert damit die strömungsbedingte Aktivierung der Thrombozyten. Nach einer definierten Zeit, die durch die Herstellung dieser Beschichtung eingestellt werden kann, wird die Beschichtung im Blutstrom resorbiert und legt nach und nach die darunterliegende Vliesstruktur frei, auf die sich nun die Endothelzellen ansiedeln können.A coating of gelatin, fibrin and / or collagen levels the microscopically rough surface of the nonwoven material, thereby reducing the flow-induced activation of the platelets. After a defined time, which can be set by the production of this coating, the coating is absorbed in the blood stream and gradually exposes the underlying nonwoven structure, on which now the endothelial cells can settle.

Außerdem wird durch eine hier beschriebene Beschichtung auch das Risiko einer Hyperplasie reduziert, da es zu einer verstärkten Abdichtung der Gefäßinnenseite nach außen kommt, die das Einströmen von Wachstumsfaktoren aus dem das Gefäß umgebenden Wundgebiet verhindert. Diese Wachstumsfaktoren haben offensichtlich einen fördernden Effekt auf die Entstehung einer Hyperplasie im Lumen der Prothese.In addition, the coating described here also reduces the risk of hyperplasia, since it leads to increased sealing the inside of the vessel comes to the outside, which prevents the influx of growth factors from the wound area surrounding the vessel. These growth factors obviously have a promoting effect on the development of hyperplasia in the lumen of the prosthesis.

Die Unterdrückung einer Hyperplasie kann zusätzlich durch das Einbinden von arzneilichen Wirkstoffen in die Beschichtung erreicht werden, die zeitgesteuert durch die Resorption der Beschichtung freigesetzt werden. Es wird daher vorgeschlagen, dass die Beschichtung ein Medikament aufweist. Zur Vorbeugung gegen eine Entzündung können Silberionen in die Beschichtung eingebunden werden.The suppression of hyperplasia can additionally be achieved by the incorporation of medicinal active substances into the coating, which are released in a time-controlled manner by the absorption of the coating. It is therefore proposed that the coating comprises a drug. To prevent inflammation, silver ions can be incorporated into the coating.

Die Beschichtung kann bei einem Implantat wie insbesondere einem implantierten künstlichen Gefäß langsam absorbiert werden. Vorteilhaft ist es, wenn sie nach ein bis 30 Tagen und vorzugsweise nach 2 bis 14 Tagen auf maximal 10 % der ursprünglichen Menge resorbiert wird. Als Meßmethode eignet sich ein in vivo Modell.The coating can be slowly absorbed in an implant, in particular an implanted artificial vessel. It is advantageous if it is absorbed after one to 30 days and preferably after 2 to 14 days to a maximum of 10% of the original amount. The measuring method is an in vivo model.

Claims (8)

  1. Structure for manufacturing vascular prostheses, having fibers that are adhesively bonded in certain places and that have a permeability for air between 0.5 ml/min*cm2 and 1.5 ml/min*cm2, wherein the structure comprises a non-woven material and the non-woven material has biocompatible properties,
    characterized in that it has at least a single-sided coating, which reduces the permeability of the structure to below 0.2 ml/min*cm2.
  2. Structure according to claim 1, characterized in that the fibers are made of polyurethane.
  3. Structure according to one of the preceding claims, characterized in that the fibers are adhesively bonded to form a cylinder and the coating is arranged at the inner surface of the cylinder.
  4. Structure according to one of the preceding claims, characterized in that the coating comprises gelatine.
  5. Structure according to one of the preceding claims, characterized in that the coating comprises collagens.
  6. Structure according to one of the preceding claims, characterized in that the coating comprises fibrin.
  7. Structure according to one of the preceding claims, characterized in that the coating comprises a medicament.
  8. Structure according to one of the preceding claims, characterized in that the coating is reabsorbed after one to 30 days and preferably after 2 to 14 days up to maximally 10% of the original amount.
EP12823134.7A 2011-12-29 2012-12-19 Fibrous structure Active EP2797640B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011122490 2011-12-29
DE102012008656A DE102012008656A1 (en) 2011-12-29 2012-05-03 Structure with fibers glued together in places
PCT/DE2012/001211 WO2013097841A1 (en) 2011-12-29 2012-12-19 Structure having fibres which are adhesively bonded to one another in locations

Publications (3)

Publication Number Publication Date
EP2797640A1 EP2797640A1 (en) 2014-11-05
EP2797640B1 true EP2797640B1 (en) 2016-07-20
EP2797640B8 EP2797640B8 (en) 2016-09-21

Family

ID=48607967

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12823134.7A Active EP2797640B8 (en) 2011-12-29 2012-12-19 Fibrous structure

Country Status (7)

Country Link
US (1) US9345808B2 (en)
EP (1) EP2797640B8 (en)
JP (1) JP6804824B2 (en)
CN (1) CN104039364B (en)
CA (1) CA2860347A1 (en)
DE (1) DE102012008656A1 (en)
WO (1) WO2013097841A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10939990B2 (en) * 2017-11-28 2021-03-09 Medtronic Vascular, Inc. Graft material having selectively advanced permeability structure and method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608158A1 (en) 1986-03-12 1987-09-17 Braun Melsungen Ag VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF
DE3913926A1 (en) * 1989-04-27 1990-10-31 Heinz Helmut Dr Med Werner Vascular prosthesis, esp. of PET with resorbable plastic coatings - esp. of poly:lactide, applied as soln. then treatment with non-solvent
US5851229A (en) * 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
US7241309B2 (en) * 1999-04-15 2007-07-10 Scimed Life Systems, Inc. Self-aggregating protein compositions and use as sealants
JPH11164881A (en) * 1997-09-17 1999-06-22 Naisemu:Kk Medical material and manufacture thereof
GB9920732D0 (en) 1999-09-03 1999-11-03 Sulzer Vascutek Ltd Sealant
US20020084178A1 (en) 2000-12-19 2002-07-04 Nicast Corporation Ltd. Method and apparatus for manufacturing polymer fiber shells via electrospinning
DE10125712B4 (en) * 2001-05-21 2012-06-06 Aesculap Ag Implant for surgery
US8101196B2 (en) * 2001-06-26 2012-01-24 Biointeractions, Ltd. Polysaccharide biomaterials and methods of use thereof
US7871946B2 (en) * 2003-10-09 2011-01-18 Kuraray Co., Ltd. Nonwoven fabric composed of ultra-fine continuous fibers, and production process and application thereof
CA2570142A1 (en) * 2004-07-07 2006-02-09 Cook Incorporated Graft, stent graft and method for manufacture
DE102006051013A1 (en) 2006-05-02 2007-11-08 Nonwotecc Medical Gmbh Surface structure for use as stent or fiber patch, has fibers adhered with one another and broken by ultrasonic treatment using ultrasonic generator, and stent drawn over arbor, where surface of arbor possesses small surface roughness
DE102006050129B3 (en) 2006-10-25 2008-01-31 Krauss-Maffei Wegmann Gmbh & Co. Kg Chain slack measuring method for use in tracked vehicle, involves fixing three extension elements at upper trough of chain such that two extension elements are arranged at length section, and third extension element is arranged on center
DE102007047246A1 (en) * 2007-09-26 2009-04-02 Aesculap Ag Reinforced vascular prosthesis with antimicrobial long-term effect
US20100119578A1 (en) * 2008-11-07 2010-05-13 Specialized Vascular Technologies, Inc. Extracellular matrix modulating coatings for medical devices
DE102009037134A1 (en) * 2009-07-31 2011-02-03 Aesculap Ag Tubular implant for replacement of natural blood vessels
CN102711662A (en) 2009-11-05 2012-10-03 无纺技术医学有限公司 Non-woven fabric for medical use and process for the preparation thereof

Also Published As

Publication number Publication date
US9345808B2 (en) 2016-05-24
CN104039364B (en) 2017-03-01
US20140364937A1 (en) 2014-12-11
DE102012008656A1 (en) 2013-07-04
JP2015503373A (en) 2015-02-02
CA2860347A1 (en) 2013-07-04
EP2797640A1 (en) 2014-11-05
WO2013097841A1 (en) 2013-07-04
EP2797640B8 (en) 2016-09-21
JP6804824B2 (en) 2020-12-23
CN104039364A (en) 2014-09-10

Similar Documents

Publication Publication Date Title
EP0248246B1 (en) Vascular graft wall
EP0248247B1 (en) Vascular graft wall
DE2508570C2 (en) Vascular prosthesis made of expanded and porous polytetrafluoroethylene
DE69728216T2 (en) Endovascular implant with controlled porosity
DE69938264T2 (en) Process for the preparation of porous, synthetic vascular grafts with oriented wax channels
DE69938295T2 (en) SMALL-LIQUID BIOLOGICAL TRANSPLANT WITH THERAPEUTIC ADMINISTRATION DEVICE
EP1579827A2 (en) Cardiovascular implant and method and device for manufacturing thereof
DE69631448T2 (en) Bypass vein graft
CN105744912A (en) Artificial vascular graft
EP1389075B1 (en) Surgical implant and method for the production
EP2797640B1 (en) Fibrous structure
DE102019121562B4 (en) Medical device for treating aneurysms
DE102009037134A1 (en) Tubular implant for replacement of natural blood vessels
DE69007999T2 (en) Prosthesis for a living organ.
DE60017899T2 (en) TISSUE TRANSPLANT FROM EXPANDED POLYTETRAFLUOROETHYLENE WITH INCREASED HEALING
EP2522309A1 (en) Valve for a heart valve prosthesis
WO2000071052A1 (en) Highly flexible coating for stents and/or stent grafts and/or vascular stent prostheses
EP1905464B1 (en) Implant and method for its production
AT404794B (en) Cardiovascular prosthesis
EP1663337A1 (en) Agent-releasing vascular prosthesis
EP4045097A1 (en) Sealant material for a medical implant
EP2515960B1 (en) Implant, method for producing such an implant, and use
DE102011000400A1 (en) Conduit-valve prosthesis e.g. conduit-cardiac valve prosthesis, for e.g. replacing deflective aorta valve for patient, has cusps formed at bulb-like projections of body, where prosthesis is integrally formed based on polyurethane-material
EP0941739A1 (en) Porous coated artificial implant material and corresponding preparation process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160211

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 813511

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160815

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: OCCLUTECH HOLDING AG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502012007739

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161020

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161021

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161121

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502012007739

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161020

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

26N No opposition filed

Effective date: 20170421

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161219

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170102

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20161231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160720

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 813511

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171219

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20230629 AND 20230705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502012007739

Country of ref document: DE

Owner name: OCCLUTECH GMBH, DE

Free format text: FORMER OWNER: OCCLUTECH HOLDING AG, SCHAFFHAUSEN, CH

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231113

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20231113

Year of fee payment: 12

Ref country code: DE

Payment date: 20231221

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231221

Year of fee payment: 12